UnitedHealthcare GLP-1 Coverage for Weight Loss (2026)
You have a UnitedHealthcare card and one question: will this plan pay for a GLP-1 medication to help you lose weight? There is no single UnitedHealthcare answer. It depends on which plan you have and what your employer or plan chose to include. Here is what UnitedHealthcare’s own published criteria say as of 2026-10-16, and how to find out where your plan stands.
Transformation Health is an independent guide, not a provider, and is not affiliated with UnitedHealthcare or Optum Rx: we do not prescribe, sell medication, or work with insurance. This content is for general education and is not medical advice. Talk with a licensed provider about your situation.
The short answer
On UnitedHealthcare commercial plans, weight loss GLP-1 coverage is an optional benefit. As of 2026-10-16, UnitedHealthcare describes its weight loss medication program as “an optional program that is put in place for clients or businesses that have elected to cover weight loss products,” with prior authorization.[1] The program lists Wegovy injection, Zepbound, and Saxenda, among other weight loss medications.[1]
If your plan has not elected that program, UnitedHealthcare’s own criteria documents say that “medications for the purpose of weight loss are typically a benefit exclusion."[2][3] So the real question is not “does UnitedHealthcare cover GLP-1s,” it is “does my plan include weight loss medications.”
Two exceptions matter:
- Some state-regulated plans. Starting October 1, 2026, UnitedHealthcare runs a separate regulatory program for certain fully insured plans in California and New York, and small group and individual plans in New Mexico and North Dakota. It covers weight loss medications with prior authorization, using a stricter BMI threshold (see the table below).[4]
- Other medical uses. For plans that exclude weight loss medications, UnitedHealthcare publishes separate criteria for Wegovy to reduce cardiovascular risk or to treat MASH (a liver condition), and for Zepbound to treat obstructive sleep apnea.[2][3]
GLP-1 medications prescribed for type 2 diabetes are a separate coverage category with their own criteria. This page is about coverage for weight management.
What UnitedHealthcare’s criteria say
UnitedHealthcare’s pharmacy benefits are run through Optum Rx, which UnitedHealthcare calls its “pharmacy service provider."[5] Our page on Optum Rx GLP-1 coverage covers the PBM side. The criteria below come from UnitedHealthcare’s own commercial pharmacy programs.
| Question | What UnitedHealthcare’s published criteria say (as of 2026-10-16) |
|---|---|
| Is weight loss coverage on every plan? | No. It is an optional program for clients that elected it; otherwise weight loss medications are typically a benefit exclusion[1][2] |
| If covered, is prior authorization required? | Yes[1] |
| Age | 12 or older for Saxenda and Wegovy injection; older than 16 for Zepbound and most others[1] |
| BMI criteria (standard program) | BMI of 30 or higher, or 27 or higher with a weight-related condition such as dyslipidemia, hypertension, type 2 diabetes, or sleep apnea[1] |
| BMI criteria (state regulatory program) | BMI of 35 or higher, documented in medical records[4] |
| Lifestyle documentation | Used alongside lifestyle modification, such as dietary changes, exercise, behavioral support, or a community-based program[1] |
| First approval | 5 months for Wegovy; 6 months for Zepbound; 4 months for Saxenda[1] |
| Renewal requirement | Continued lifestyle modification plus a loss of at least 5 percent of baseline body weight (4 percent for Saxenda); renewals run 12 months[1] |
| Still adjusting the dose? | A one-time additional 6-month approval for people on therapy six months or less who have not reached a maintenance dose[1] |
| Wegovy tablets | UnitedHealthcare notes they are “typically excluded from coverage”[1] |
These criteria can be changed by state mandates, federal requirements, and your specific benefit plan, as UnitedHealthcare’s own documents note.[1] Your plan documents are the only version that counts for you.
If your plan excludes weight loss medications
UnitedHealthcare’s separate criteria for other medical uses, as of 2026-10-16:
- Wegovy for cardiovascular risk reduction (effective May 1, 2026): age 45 or older, a BMI of 27 or higher, and medical records showing established cardiovascular disease, such as a prior heart attack or stroke, or symptomatic peripheral arterial disease. People with a prior heart attack must also be on standard heart medications unless they cannot take them, and the criteria exclude people with a diabetes diagnosis. Approvals run 12 months.[2]
- Wegovy injection for MASH (same document): medical records showing the liver condition at fibrosis stage F2 or F3.[2]
- Zepbound for obstructive sleep apnea (effective September 1, 2026): age 18 or older, a BMI of 30 or higher, a sleep study showing moderate to severe sleep apnea, at least one earlier dietary effort to lose weight, continued symptoms despite PAP therapy or not being a candidate for it, no diabetes diagnosis, and a prescriber who is a sleep specialist or experienced with sleep apnea. A first approval runs 6 months.[3]
These match uses on the FDA labels: Wegovy is approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and Wegovy injection to treat MASH with moderate to advanced liver fibrosis; Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity.[11][12] Both labels carry a boxed warning about the risk of thyroid C-cell tumors. A licensed provider decides whether any of these uses applies to you.
What changed in 2026
May 1, 2026. The current version of UnitedHealthcare’s Wegovy criteria for plans that exclude weight loss medications (cardiovascular risk reduction and MASH) took effect.[2]
September 1, 2026. The current version of UnitedHealthcare’s Zepbound criteria for obstructive sleep apnea took effect.[3]
October 1, 2026. UnitedHealthcare started the separate state regulatory program for California, New Mexico, New York, and North Dakota plans, and updated its standard weight loss program to add the one-time extra 6-month approval for people still adjusting their dose and to note that Wegovy tablets are typically excluded.[4][6]
UnitedHealthcare revises these criteria regularly, and employers revisit their plan decisions every plan year. A benefit you have this year is worth confirming again at open enrollment.
Medicare Advantage, Medicaid, and individual plans
Medicare Advantage. Federal law lets Medicare Part D exclude drugs “when used for anorexia, weight loss, or weight gain,” and as of 2026-10-16 that exclusion is still in the statute.[9] Medicare Advantage plans with drug coverage can cover a GLP-1 for other approved uses, such as type 2 diabetes. Separately, CMS is running the Medicare GLP-1 Bridge, a demonstration for eligible Part D enrollees from July 1, 2026 through December 31, 2027.[10] Our pages on Medicare Part D and GLP-1 coverage and the Medicare GLP-1 Bridge explain both.
Medicaid plans. UnitedHealthcare Community Plan coverage follows each state’s Medicaid rules, which differ by state. Call the member services number on your card.
Individual and family plans. Outside the state regulatory program above, coverage varies by plan and state. Check your plan’s drug list and benefit summary, or call member services.
How to check your own plan
You do not need to wait for a denial letter. Three routes, fastest first:
Ask your HR benefits team. If you get insurance through work, the decisive fact is whether your employer elected weight loss medication coverage. HR or your benefits portal can answer that directly.
Call member services. Use the number on your insurance card and ask three questions. Does my plan include coverage for weight loss medications? If so, which GLP-1 medications are covered and which prior authorization criteria apply? Is my plan part of the state regulatory program?
Check your plan’s drug list. Log in to your member account and search for semaglutide or tirzepatide. Read the notes; a listing for type 2 diabetes does not mean weight management is covered.
If the benefit exists, your next step is the paperwork. Our guide to GLP-1 prior authorization walks through the documentation these requests usually need, including the BMI record and lifestyle notes that UnitedHealthcare’s criteria ask for.
If your plan says no
Plenty of people with UnitedHealthcare cards land here, through no fault of their own. What you do next depends on why the answer was no.
The denial was about criteria or documentation. This is often fixable. A documented BMI from a recent visit, weight-related conditions noted explicitly in your chart, and recorded lifestyle efforts address the criteria above. HealthCare.gov says you generally have 180 days from a denial notice to file an internal appeal, and if that appeal is denied, you can in many cases ask for an independent external review.[7][8] For employer plans covered by the federal claims rule, a decision on a request that needs approval in advance is generally due within 15 days, or 72 hours if urgent.[14] Start with our guide on what to do when insurance denies your GLP-1.
Your plan does not include the benefit. An appeal generally cannot override a plan exclusion, because the medication is not a covered benefit on your plan. For individual and small-group plans that must cover essential health benefits, federal rules require a process to request a drug the plan does not otherwise cover, decided within 72 hours, or 24 hours if urgent.[13] You can also ask HR whether weight loss coverage is under consideration for the next plan year, check whether another plan at open enrollment includes it, and ask your prescriber whether a covered use such as cardiovascular risk reduction or sleep apnea applies to you. Beyond that, the options are outside insurance:
- Manufacturer savings and self-pay options. Novo Nordisk and Eli Lilly each publish savings and self-pay terms, and the terms change. Our page on GLP-1 savings programs compares them.
- Cash-pay telehealth programs. Some prescribe brand-name medications and some prescribe compounded medications. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products.[15] Our page on compounded GLP-1 without insurance explains how that route works.
Prices vary by program, medication, and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms. At most telehealth programs, a licensed provider reviews your health history and decides whether a prescription is appropriate. The full insurance coverage overview can help you weigh the options side by side.
Transformation Health does not accept payment from providers. How we make money.
We're relaunching soon
We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.
Get StartedCitations
[1] UnitedHealthcare Pharmacy. Clinical Pharmacy Program 2026 P 1114-23, “Prior Authorization/Notification - Weight Loss/Appetite Suppression Medication Coverage.” Effective 10/1/2026. Accessed 2026-10-16. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
[2] UnitedHealthcare Pharmacy. Clinical Pharmacy Program 2026 P 1445-4, “Prior Authorization/Non-Formulary - Wegovy (semaglutide) injection, Wegovy (semaglutide) tablets - Cardiovascular Risk Reduction and MASH Only.” Effective 5/1/2026. Accessed 2026-10-16. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Non-Formulary-Wegovy.pdf
[3] UnitedHealthcare Pharmacy. Clinical Pharmacy Program 2026 P 1475-3, “Prior Authorization/Non-Formulary - Zepbound (tirzepatide) - Obstructive Sleep Apnea Only.” Effective 9/1/2026. Accessed 2026-10-16. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Non-Formulary-Zepbound.pdf
[4] UnitedHealthcare Pharmacy. Clinical Pharmacy Program 2026 P 4039-1, “Prior Authorization/Regulatory - California, New Mexico (Small Group and Individual), New York, North Dakota EHB (Small Group and Individual) Regulatory Fully Insured Program - Weight Loss.” Effective 10/1/2026. Accessed 2026-10-16. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Regulatory-Weight-Loss.pdf
[5] UnitedHealthcare. “Pharmacy benefits” (member resources; “What is Optum Rx?”). Accessed 2026-10-16. https://www.uhc.com/member-resources/pharmacy-benefits
[6] UnitedHealthcare. Commercial Business Bulletin (10/1/2026), “Pharmacy Update - Notice of Changes to Prior Authorization Requirements and Coverage Criteria for UnitedHealthcare Commercial.” Accessed 2026-10-16. https://www.uhcprovider.com/content/dam/provider/docs/public/resources/pharmacy/COMM-Pharmacy-Update-Prior-Auth-and-Coverage-Criteria.pdf
[7] HealthCare.gov (Centers for Medicare and Medicaid Services). “Internal appeals.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
[8] HealthCare.gov (Centers for Medicare and Medicaid Services). “External review.” Accessed 2026-10-16. https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
[9] 42 U.S.C. 1395w-102(e)(2)(A) (definition of covered Part D drug; exclusions), incorporating 42 U.S.C. 1396r-8(d)(2)(A). Accessed 2026-10-16. https://www.law.cornell.edu/uscode/text/42/1395w-102
[10] Centers for Medicare and Medicaid Services. “Medicare GLP-1 Bridge.” Accessed 2026-10-16. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
[11] Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. U.S. Food and Drug Administration. Revised 06/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf
[12] Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. U.S. Food and Drug Administration. Revised 08/2026. Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf
[13] 45 CFR 156.122(c) (prescription drug benefits: standard and expedited exception requests). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/45/156.122
[14] 29 CFR 2560.503-1(f)(2) (claims procedure for employee benefit plans: urgent care and pre-service claim decision deadlines). Accessed 2026-10-16. https://www.law.cornell.edu/cfr/text/29/2560.503-1
[15] U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” Accessed 2026-10-16. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Important disclosures
Coverage information on this page is current as of 2026-10-16, is general and educational, and changes frequently. It does not represent the terms of your specific plan and is not legal advice. To verify coverage for your plan, call the member services number on your UnitedHealthcare card, or ask your HR benefits team if you get insurance through work.
Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation. transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. A licensed provider decides whether a prescription is appropriate. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as brand-name products. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound and may differ in formulation, purity, and potency. Wegovy and Saxenda are trademarks of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. UnitedHealthcare, UnitedHealthcare Community Plan, and Optum Rx are trademarks of their respective owners. Transformation Health is not affiliated with or endorsed by UnitedHealthcare, Optum Rx, Novo Nordisk, or Eli Lilly. Transformation Health does not accept payment from providers. How we make money.